Paolo A Cortesi
Overview
Explore the profile of Paolo A Cortesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belli L, Panariello A, Perricone G, Prandoni P, Vigano R, Mazzarelli C, et al.
Transpl Int
. 2025 Jan;
37():13451.
PMID: 39834690
Patients with severe alcoholic hepatitis SAH may suffer of undiagnosed psychiatric illnesses, typically depression. Assessment of prevalence and potential impact of psychiatric disturbances on alcohol relapse after LT, were the...
2.
Conti S, Fornari C, Ferrara P, Antonazzo I, Madotto F, Traini E, et al.
Int J Public Health
. 2024 May;
69:1607320.
PMID: 38818229
[This corrects the article DOI: 10.3389/ijph.2023.1605959.].
3.
Conti S, Fornari C, Ferrara P, Antonazzo I, Madotto F, Traini E, et al.
Int J Public Health
. 2023 Jun;
68:1605959.
PMID: 37347013
We explored temporal variations in disease burden of ambient particulate matter 2.5 μm or less in diameter (PM) and ozone in Italy using estimates from the Global Burden of Disease...
4.
Artzner T, Conti S, Cortesi P, Sacleux S, Fernandez J, Morelli M, et al.
Liver Transpl
. 2022 May;
28(9):1429-1440.
PMID: 35544360
There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice...
5.
Cortesi P, Fornari C, Capra R, Cozzolino P, Patti F, Mantovani L
Value Health
. 2022 Apr;
25(9):1489-1498.
PMID: 35484029
Objectives: Improving the understanding of multiple sclerosis (MS) mechanism and disability progression over time is essential to assess the value of healthcare interventions. Poor or no data on disability progression...
6.
Zanetti A, Sakellariou G, Zambon A, Carrara G, Argnani L, Mantovani L, et al.
Arthritis Care Res (Hoboken)
. 2022 Apr;
75(5):1046-1051.
PMID: 35439369
Objective: Early diagnosis and tight control improve outcomes of rheumatoid arthritis (RA). However, whether establishing an early arthritis clinic (EAC) is sustainable for national health systems is not known. This...
7.
Ferrara P, Di Laura D, Cortesi P, Mantovani L
PLoS One
. 2021 Jul;
16(7):e0254631.
PMID: 34252164
Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases...
8.
Cortesi P, Fornari C, Madotto F, Conti S, Naghavi M, Bikbov B, et al.
Eur J Prev Cardiol
. 2021 May;
28(4):385-396.
PMID: 33966080
Aims: An exhaustive and updated estimation of cardiovascular disease burden and vascular risk factors is still lacking in European countries. This study aims to fill this gap assessing the global...
9.
Belli L, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi P, et al.
J Hepatol
. 2021 May;
75(3):610-622.
PMID: 33951535
Background & Aims: Liver transplantation (LT) has been proposed as an effective salvage therapy even for the sickest patients with acute-on-chronic liver failure (ACLF). This large collaborative study was designed...
10.
Ferrara P, Cortesi P, Di Laura D, Maggioni A, Mantovani L
Clin Drug Investig
. 2021 Mar;
41(5):459-468.
PMID: 33725323
Background: Rivaroxaban is a selective inhibitor of coagulation factor Xa and its combination with aspirin showed better outcomes in the prevention of recurrent cardiovascular disease than aspirin alone. Objective: This...